Xeris Biopharma (XERS) Short Interest Ratio & Short Volume $4.26 +0.03 (+0.59%) As of 10:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Xeris Biopharma Short Interest DataXeris Biopharma (XERS) has a short interest of 10.27 million shares, representing 7.22% of the float (the number of shares available for trading by the public). This marks a -2.10% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.3, indicating that it would take 6.3 days of the average trading volume of 1.90 million shares to cover all short positions.Current Short Interest10,270,000 sharesPrevious Short Interest10,490,000 sharesChange Vs. Previous Month-2.10%Dollar Volume Sold Short$36.87 millionShort Interest Ratio6.3 Days to CoverLast Record DateFebruary 15, 2025Outstanding Shares149,081,000 sharesShort Percent of Float7.22%Today's Trading Volume442,155 sharesAverage Trading Volume1,901,538 sharesToday's Volume Vs. Average23% Short Selling Xeris Biopharma? Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXERS Short Interest Over TimeXERS Days to Cover Over TimeXERS Percentage of Float Shorted Over Time Remove Ads Xeris Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/202510,270,000 shares $36.87 million -2.1%7.2%6.3 $3.59 1/31/202510,490,000 shares $37.34 million +1.3%N/A6.2 $3.56 1/15/202510,360,000 shares $33.57 million +1.7%N/A6.3 $3.24 12/31/202410,190,000 shares $34.54 million +7.0%N/A6.4 $3.39 12/15/20249,520,000 shares $31.23 million -3.9%N/A6.1 $3.28 11/30/20249,910,000 shares $32.50 million -2.4%N/A6.1 $3.28 11/15/202410,150,000 shares $29.64 million -10.7%N/A6.4 $2.92 10/31/202411,370,000 shares $36.61 million -1.7%N/A7.2 $3.22 10/15/202411,570,000 shares $34.94 million +4.3%N/A7.7 $3.02 9/30/202411,090,000 shares $31.61 million +0.8%N/A7.2 $2.85 Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 9/15/202411,000,000 shares $31.68 million +2.7%N/A7.1 $2.88 8/31/202410,710,000 shares $30.10 million -0.9%N/A7.6 $2.81 8/15/202410,810,000 shares $28.32 million -3.7%N/A7.5 $2.62 7/31/202411,220,000 shares $27.83 million -1.7%N/A7.9 $2.48 7/15/202411,410,000 shares $28.30 million +3.7%N/A8.7 $2.48 6/30/202411,000,000 shares $24.75 million -0.8%N/A8.2 $2.25 6/15/202411,088,000 shares $24.39 million -2.1%N/A7.9 $2.20 5/31/202411,330,000 shares $25.55 million +5.0%N/A7.3 $2.26 5/15/202410,790,000 shares $21.36 million +11.9%N/A6.4 $1.98 4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75 4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85 3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21 3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23 2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08 2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21 1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46 1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77 12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35 12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02 11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86 11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47 10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83 10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58 9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86 9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00 8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27 8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23 7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61 7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54 6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62You are in denial—here’s why (Ad)During volatile market moves like the one we're in now, most people "freeze up." This is the "Denial" stage of a market downturn. Yes, the market is down—but this volatility is NOT over. And it's NOT too late to take action. Do it now.To learn more click here 6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71 5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56 5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84 4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26 4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17 3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63 3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30 2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38 2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26 1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24 1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28 12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33 12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34 11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50 11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39 10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60 10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22 9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56 9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79 8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67 8/15/20229,620,000 shares $18.18 million -7.1%N/A7.5 $1.89 7/31/202210,350,000 shares $14.70 million +4.9%N/A6.1 $1.42 7/15/20229,870,000 shares $14.11 million -3.3%N/A5.5 $1.43 6/30/202210,210,000 shares $15.72 million +64.7%N/A5.6 $1.54 6/15/20226,200,000 shares $10.91 million -8.3%N/A3.3 $1.76 5/31/20226,760,000 shares $14.94 million +9.0%N/A3.7 $2.21 5/15/20226,200,000 shares $10.60 million +14.6%N/A3.4 $1.71 4/30/20225,410,000 shares $13.20 million +20.2%N/A3.3 $2.44 4/15/20224,500,000 shares $11.03 million +12.8%N/A2.6 $2.45 3/31/20223,990,000 shares $10.21 million -23.4%N/A2.1 $2.56 3/15/20225,210,000 shares $13.91 million -1.7%N/A1.7 $2.67 2/28/20225,300,000 shares $12.61 million -17.3%N/A1.8 $2.38 2/15/20226,410,000 shares $16.47 million -3.5%N/A2.1 $2.57 1/31/20226,640,000 shares $14.01 million +41.6%N/A2.1 $2.11 1/15/20224,690,000 shares $10.41 million +27.5%N/A1.5 $2.22 12/31/20213,680,000 shares $10.78 million +4.3%N/A0 $2.93 12/15/20213,530,000 shares $8.01 million +16.1%N/A1.9 $2.27 11/30/20213,040,000 shares $6.35 million -30.9%N/A1.8 $2.09 11/15/20214,400,000 shares $10.91 million +14.6%N/A2.4 $2.48 10/29/20213,840,000 shares $7.14 million +13.6%N/A1.1 $1.86 10/15/20213,380,000 shares $6.76 million -17.2%N/A1 $2.00 9/30/20214,080,000 shares $10.00 million -5.1%N/A1.2 $2.45 9/15/20214,300,000 shares $10.97 million -12.1%6.6%1.2 $2.55 8/31/20214,890,000 shares $13.50 million +9.9%7.6%1.2 $2.76 8/13/20214,450,000 shares $10.32 million -17.3%6.9%1 $2.32 7/30/20215,380,000 shares $16.52 million +0.6%8.2%1.8 $3.07 7/15/20215,350,000 shares $18.89 million -60.1%8.3%1.8 $3.53 6/30/202113,400,000 shares $54.54 million -13.9%20.7%4.4 $4.07 6/15/202115,570,000 shares $64.46 million +1.8%24.0%5.4 $4.14 5/28/202115,290,000 shares $47.70 million +0.1%23.6%5.2 $3.12You are in denial—here’s why (Ad)During volatile market moves like the one we're in now, most people "freeze up." This is the "Denial" stage of a market downturn. Yes, the market is down—but this volatility is NOT over. And it's NOT too late to take action. Do it now.To learn more click here 5/14/202115,270,000 shares $48.71 million +14.4%N/A6.4 $3.19 4/30/202113,350,000 shares $51.66 million -1.6%N/A5.3 $3.87 4/15/202113,560,000 shares $55.19 million -1.1%N/A5.2 $4.07 3/31/202113,710,000 shares $57.72 million +29.1%N/A5 $4.21 3/15/202110,620,000 shares $51.08 million +24.8%N/A3.9 $4.81 2/26/20218,510,000 shares $46.08 million +44.5%N/A3.6 $5.42 2/12/20215,890,000 shares $39.05 million +22.0%N/A2.7 $6.63 1/29/20214,830,000 shares $25.16 million -10.6%N/A2.4 $5.21 1/15/20215,400,000 shares $31.00 million +6.3%N/A3.1 $5.74 12/31/20205,080,000 shares $25.96 million -3.8%N/A2.9 $5.11 12/15/20205,280,000 shares $24.50 million -22.8%N/A3.1 $4.64 11/30/20206,840,000 shares $30.99 million -53.8%N/A3.5 $4.53 10/30/202014,500,000 shares $71.34 million -18.0%N/A4.6 $4.92 10/15/202017,680,000 shares $94.94 million +0.9%N/A5.1 $5.37 9/30/202017,530,000 shares $103.95 million +9.5%N/A4.7 $5.93 9/15/202016,010,000 shares $88.86 million -3.7%N/A3.7 $5.55 8/31/202016,620,000 shares $78.11 million +9.2%N/A4.3 $4.70 8/14/202015,220,000 shares $63.77 million +14.6%N/A4.7 $4.19 7/31/202013,280,000 shares $37.98 million +17.8%N/A5.7 $2.86 7/15/202011,270,000 shares $31.89 million +78.3%N/A5.8 $2.83 6/30/20206,320,000 shares $16.81 million +354.7%N/A4.3 $2.66 6/15/20201,390,000 shares $6.27 million -0.7%N/A2.4 $4.51 5/29/20201,400,000 shares $7.49 million -40.2%N/A2.2 $5.35 5/15/20202,340,000 shares $8.85 million +10.4%N/A3.6 $3.78 4/30/20202,120,000 shares $5.72 million +16.5%N/A2.9 $2.70 4/15/20201,820,000 shares $3.20 million +5.2%N/A3 $1.76 3/31/20201,730,000 shares $3.37 million +9.4%N/A3.1 $1.95 3/13/20201,582,100 shares $3.10 million +4.8%7.0%2.6 $1.96 XERS Short Interest - Frequently Asked Questions What is Xeris Biopharma's current short interest? Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been covered or closed out. As of February 15th, investors have sold 10,270,000 shares of XERS short. 7.22% of Xeris Biopharma's shares are currently sold short. Learn More on Xeris Biopharma's current short interest. What is a good short interest ratio for Xeris Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 6.0. Learn More on Xeris Biopharma's short interest ratio. Which institutional investors are shorting Xeris Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Xeris Biopharma: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Xeris Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.22% of Xeris Biopharma's floating shares are currently sold short. Is Xeris Biopharma's short interest increasing or decreasing? Xeris Biopharma saw a decrease in short interest in February. As of February 15th, there was short interest totaling 10,270,000 shares, a decrease of 2.1% from the previous total of 10,490,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Xeris Biopharma's short interest compare to its competitors? 7.22% of Xeris Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Xeris Biopharma: Denali Therapeutics Inc. (6.97%), Beam Therapeutics Inc. (11.65%), ImmunityBio, Inc. (49.24%), Centessa Pharmaceuticals plc (5.20%), Mesoblast Limited (2.19%), Kymera Therapeutics, Inc. (13.46%), CG Oncology, Inc. (17.44%), Agios Pharmaceuticals, Inc. (8.39%), NewAmsterdam Pharma (5.28%), Harmony Biosciences Holdings, Inc. (8.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks. What does it mean to sell short Xeris Biopharma stock? Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Xeris Biopharma? A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further. How often is Xeris Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is February, 15 2025. More Short Interest Resources from MarketBeat Related Companies DNLI Short Interest Data BEAM Short Interest Data IBRX Short Interest Data CNTA Short Interest Data MESO Short Interest Data KYMR Short Interest Data CGON Short Interest Data AGIO Short Interest Data NAMS Short Interest Data HRMY Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XERS) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredAI Shock Coming on March 18? Prepare NowIf you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredYou are in denial—here’s whyDuring volatile market moves like the one we're in now, most people "freeze up." This is the "Denial" stage...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
